By inhibiting SGLT-1, sotagliflozin delays glucose absorption in the distal small intestine and colon, consequently reducing Post Prandial Glucose (PPG) and improving glycemic control in type 2 diabetes subjects [15, 41]. Here, SLC5A1 is linked to type 2 diabetes mellitus.